Sharon Townson
Vermögen: 1 Mio $ am 31.05.2026
Vermögen: 1 Mio $ am 31.05.2026
Dr. Sharon Townson is a Chief Scientific Officer at Monte Rosa Therapeutics, Inc. Dr. Townson was previously employed as an Executive Director & Head-Platform Biology by Kymera Therapeutics, Inc. and a Scientific Director-Physical Biochemistry by Warp Drive Bio, Inc. She received her undergraduate degree from the University of Salford and a doctorate degree from the University of Manchester Institute of Science & Technology.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 17.06.2026 | 67’845 ( 0.08% ) | 1 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2021 |
| Unternehmen | Position | Ende |
|---|---|---|
| KYMERA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.06.2020 |
Warp Drive Bio, Inc.
Warp Drive Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Focuses on proprietary genomic technology to discover drugs of natural origin | Corporate Officer/Principal | 01.12.2018 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
University of Salford
University of Salford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Manchester Institute of Science & Technology
University of Manchester Institute of Science & Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Warp Drive Bio, Inc.
Warp Drive Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Focuses on proprietary genomic technology to discover drugs of natural origin | Commercial Services |
Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops immunology medicines for health problems | Health Technology |
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen